A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients With Resectable Cutaneous Squamous... by D. Schadendorf, S. Koyfman, A.W. Silk, D. Davar, J. Clark, R. Ladwa, J. Lee, L.H. Suttner, R. Groisberg, F. Jin, G. Hanna

Get full text

Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting by L. Mortier, R. Gutzmer, V. Atkinson, S. Dalle, P. Saiag, B. Neyns, A. Rorive, P. Parente, M. Weichenthal, J.-J. Grob, C. Lebbé, P. Mohr, T. Eigentler, L. McDonald, L. Willemot, F. Brellier, O. Bakharevski, S. Houssou, M. Jadhao, D. Schadendorf

Get full text

Sex differences and its impact on treatment outcomes of advanced melanoma in Germany – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG by A.-S. Leven, T. Peters, L.S. Rajcsanyi, M. Weichenthal, P. Mohr, F. Meier, I. von Wasielewski, R. Gutzmer, J. Utikal, P. Terheyden, R. Herbst, S. Haferkamp, C. Pföhler, U. Leiter, A. Kreuter, C. Gebhardt, C. Weishaupt, S. Grabbe, D. Debus, J.C. Hassel, A. Tasdogan, J.-M. Placke, L. Zimmer, E. Livingstone, D. Schadendorf, A. Roesch, A. Hinney, S. Ugurel

Get full text